Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Medical Microbiology and Immunology
Erschienen in: Medical Microbiology and Immunology 6/2016

12.08.2016 | Review

Prospects of a vaccine for the prevention of congenital cytomegalovirus disease

verfasst von: Bodo Plachter

Erschienen in: Medical Microbiology and Immunology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Congenital human cytomegalovirus (HCMV) infection is one leading cause of childhood disabilities. Prevention of congenital HCMV disease by vaccination has consequently been identified as a priority public healthcare goal. Several vaccine candidates have been introduced in the past that aimed at the prevention of primary HCMV infection in pregnancy. None of these has provided complete protection, and no licensed vaccine is thus far available. An additional level of complexity has been reached by recent studies indicating that the burden of HCMV transmission and disease following non-primary infections in pregnancy may be higher than previously anticipated. Substantial progress in our understanding of the immunobiology of HCMV infection in pregnancy has fostered studies to test revised or novel vaccine strategies. Preventing HCMV transmission has been identified a surrogate endpoint, rendering the conduction of vaccine studies feasible with reasonable effort. Identification of the glycoprotein complex gH/gL/UL128-131 as a mediator of HCMV host cell tropism and evaluation of that complex as a major target of the neutralizing antibody response made manufacturers consider vaccine candidates that include these proteins. Detailed structural analyses of the neutralizing determinants on HCMV glycoprotein B (gB) have revived interest in using this protein in its pre-fusion conformation for vaccine purposes. Studies in pregnant women and in animal models have provided evidence that addressing the T lymphocyte response by vaccination may be crucial to prevent HCMV transmission to the offspring. CD4 T lymphocytes may be of particular importance in this respect. A simultaneous targeting of both the humoral and cellular immune response against HCMV by vaccination thus appears warranted in order to prevent congenital HCMV infection. There is, however, still need for further research to be able to define an immunological correlate of protection against HCMV transmission during pregnancy. This brief review will highlight recent developments in our understanding of the natural history and immunobiology of HCMV infection in pregnancy and their possible impact on the strategies for the development of an HCMV vaccine.
Literatur
1.
Boppana SB, Ross SA, Shimamura M, Palmer AL, Ahmed A, Michaels MG, Sanchez PJ, Bernstein DI, Tolan RW Jr, Novak Z, Chowdhury N, Britt WJ, Fowler KB (2011) Saliva polymerase-chain-reaction assay for cytomegalovirus screening in newborns. New Engl J Med 364:2111–2118PubMedPubMedCentralCrossRef
2.
Mussi-Pinhata MM, Yamamoto AY, Moura Brito RM, de Lima Isaac M, de Carvalhoe Oliveira PF, Boppana S, Britt WJ (2009) Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis 49:522–528PubMedPubMedCentralCrossRef
3.
Cannon MJ, Grosse SD, Fowler KB (2013) The epidemiology and public health impact of congenital cytomegalovirus infection. In: Reddehase MJ (ed) Cytomegaloviruses From molecular pathogenesis to intervention. Caister Academic Press, Norfolk, pp 26–48
4.
Pass RF, Stagno S, Myers GJ, Alford CA (1980) Outcome of symptomatic congenital cytomegalovirus infection: results of long-term longitudinal follow-up. Pediatrics 66:758–762PubMed
5.
Boppana SB, Pass RF, Britt WJ, Stagno S, Alford CA (1992) Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J 11:93–99PubMedCrossRef
6.
Dreher AM, Arora N, Fowler KB, Novak Z, Britt WJ, Boppana SB, Ross SA (2014) Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection. J Pediatr 164:855–859PubMedPubMedCentralCrossRef
7.
8.
Britt W (2015) Controversies in the natural history of congenital human cytomegalovirus infection: the paradox of infection and disease in offspring of women with immunity prior to pregnancy. Med Microbiol Immunol 204:263–271PubMedCrossRef
9.
Boppana SB, Britt WJ (2013) Synopsis of clinical aspects of human cytomegalovirus disease. In: Reddehase MJ (ed) Cytomegaloviruses From molecular pathogenesis to intervention. Caister Academic Press, Norfolk, pp 1–25
10.
11.
Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R (2004) Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 39:233–239PubMedCrossRef
12.
Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, Ljungman P, Mocarski ES, Pass RF, Read JS, Schleiss MR, Plotkin SA (2013) Priorities for CMV vaccine development. Vaccine 32:4–10PubMedPubMedCentralCrossRef
13.
Elek SD, Stern H (1974) Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1:1–5PubMedCrossRef
14.
Plotkin SA, Furukawa T, Zygraich N, Huygelen C (1975) Candidate cytomegalovirus strain for human vaccination. Infect Immun 12:521–527PubMedPubMedCentral
15.
Plotkin SA, Plachter B (2013) Cytomegalovirus Vaccine: On the Way to the Future? In: Reddehase MJ (ed) Cytomegaloviruses: From molecular pathogenesis to intervention. Caister Academic Press, Norfolk, pp 424–449
16.
Plotkin S (2015) The history of vaccination against cytomegalovirus. Med Microbiol Immunol 204:247–254PubMedCrossRef
17.
Dasari V, Smith C, Khanna R (2013) Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases. Expert Rev Vaccines 12:661–676PubMedCrossRef
18.
McCormick AL, Mocarski ES (2015) The immunological underpinnings of vaccinations to prevent cytomegalovirus disease. Cell Mol Immunol 12:170–179PubMedCrossRef
19.
Schleiss MR, Heineman TC (2005) Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev Vaccines 4:381–406PubMedCrossRef
20.
Fu TM, An Z, Wang D (2014) Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease. Vaccine 32:2525–2533PubMedCrossRef
21.
Kenneson A, Cannon MJ (2007) Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17:253–276PubMedCrossRef
22.
Enders G, Daiminger A, Bader U, Exler S, Enders M (2011) Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 52:244–246PubMedCrossRef
23.
Stagno S, Pass RF, Cloud G, Britt WJ, Henderson RE, Walton PD, Veren DA, Page F, Alford CA (1986) Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 256:1904–1908PubMedCrossRef
24.
Townsend CL, Forsgren M, Ahlfors K, Ivarsson SA, Tookey PA, Peckham CS (2013) Long-term outcomes of congenital cytomegalovirus infection in Sweden and the United Kingdom. Clin Infect Dis 56:1232–1239PubMedPubMedCentralCrossRef
25.
Ahlfors K, Ivarsson SA, Harris S (2001) Secondary maternal cytomegalovirus infection—a significant cause of congenital disease. Pediatrics 107:1227–1228PubMedCrossRef
26.
Ross SA, Fowler KB, Ashrith G, Stagno S, Britt WJ, Pass RF, Boppana SB (2006) Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. J Pediatr 148:332–336PubMedCrossRef
27.
Yamamoto AY, Mussi-Pinhata MM, Boppana SB, Novak Z, Wagatsuma VM, Oliveira PF, Duarte G, Britt WJ (2010) Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol 202:297–298PubMedCrossRef
28.
Ahlfors K, Ivarsson SA, Harris S, Svanberg L, Holmqvist R, Lernmark B, Theander G (1984) Congenital cytomegalovirus infection and disease in Sweden and the relative importance of primary and secondary maternal infections. Preliminary findings from a prospective study. Scand J Infect Dis 16:129–137PubMedCrossRef
29.
Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ (2001) Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. New Engl J Med 344:1366–1371PubMedCrossRef
30.
Dar L, Pati SK, Patro AR, Deorari AK, Rai S, Kant S, Broor S, Fowler KB, Britt WJ, Boppana SB (2008) Congenital cytomegalovirus infection in a highly seropositive semi-urban population in India. Pediatr Infect Dis J 27:841–843PubMedCrossRef
31.
van der Sande MA, Kaye S, Miles DJ, Waight P, Jeffries DJ, Ojuola OO, Palmero M, Pinder M, Ismaili J, Flanagan KL, Aveika AA, Zaman A, Rowland-Jones S, McConkey SJ, Whittle HC, Marchant A (2007) Risk factors for and clinical outcome of congenital cytomegalovirus infection in a peri-urban West-African birth cohort. PLoS One 2:e492PubMedPubMedCentralCrossRef
32.
Wang C, Zhang X, Bialek S, Cannon MJ (2011) Attribution of congenital cytomegalovirus infection to primary versus non-primary maternal infection. Clin Infect Dis 52:e11–e13PubMedCrossRef
33.
Hyde TB, Schmid DS, Cannon MJ (2010) Cytomegalovirus seroconversion rates and risk factors: implications for congenital CMV. Rev Med Virol 20:311–326PubMedCrossRef
34.
Klenovsek K, Weisel F, Schneider A, Appelt U, Jonjic S, Messerle M, Bradel-Tretheway B, Winkler TH, Mach M (2007) Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110:3472–3479PubMedCrossRef
35.
Cekinovic D, Golemac M, Pugel EP, Tomac J, Cicin-Sain L, Slavuljica I, Bradford R, Misch S, Winkler TH, Mach M, Britt WJ, Jonjic S (2008) Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J Virol 82:12172–12180PubMedPubMedCentralCrossRef
36.
Maidji E, Nigro G, Tabata T, McDonagh S, Nozawa N, Shiboski S, Muci S, Anceschi MM, Aziz N, Adler SP, Pereira L (2010) Antibody treatment promotes compensation for human cytomegalovirus-induced pathogenesis and a hypoxia-like condition in placentas with congenital infection. Am J Pathol 177:1298–1310PubMedPubMedCentralCrossRef
37.
Kauvar LM, Liu K, Park M, DeChene N, Stephenson R, Tenorio E, Ellsworth SL, Tabata T, Petitt M, Tsuge M, Fang-Hoover J, Adler SP, Cui X, McVoy MA, Pereira L (2015) A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types. Antimicrob Agents Chemother 59:1558–1568PubMedPubMedCentralCrossRef
38.
Nigro G, Adler SP, La TR, Best AM (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. New Engl J Med 353:1350–1362PubMedCrossRef
39.
Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, Guaschino S, Vergani P, Todros T, Frusca T, Arossa A, Furione M, Rognoni V, Rizzo N, Gabrielli L, Klersy C, Gerna G (2014) A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. New Engl J Med 370:1316–1326PubMedCrossRef
40.
Patel HD, Nikitin P, Gesner T, Lin JJ, Barkan DT, Ciferri C, Carfi A, Akbarnejad YT, Skewes-Cox P, Wiedmann B, Jarousse N, Zhong W, Feire A, Hebner CM (2016) In vitro characterization of human cytomegalovirus-targeting therapeutic monoclonal antibodies LJP538 and LJP539. Antimicrob Agents Chemother 60:4961–4971PubMedCrossRef
41.
Dole K, Segal FP, Feire A, Magnusson B, Rondon JC, Vemula J, Yu J, Pang Y, Pertel P (2016) A first-in-human study to assess the safety and pharmacokinetics of monoclonal antibodies against human cytomegalovirus in healthy volunteers. Antimicrob Agents Chemother 60:2881–2887PubMedPubMedCentralCrossRef
42.
Frenzel K, Lehmann J, Krüger DH, Martin-Parras L, Uharek L, Hofmann J (2014) Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection. Med Microbiol Immunol 203:115–123PubMedCrossRef
43.
Mach M, Wiegers AK, Spindler N, Winkler TH (2013) Protective humoral immunity. In: Reddehase MJ (ed) Cytomegaloviruses From molecular pathogenesis to intervention. Caister Academic Press, Norfolk, pp 215–231
44.
Britt WJ, Vugler L, Butfiloski EJ, Stephens EB (1990) Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64:1079–1085PubMedPubMedCentral
45.
Marshall GS, Rabalais GP, Stout GG, Waldeyer SL (1992) Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis 165:381–384PubMedCrossRef
46.
Schoppel K, Kropff B, Schmidt C, Vornhagen R, Mach M (1997) The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. J Infect Dis 175:533–544PubMedCrossRef
47.
Rothe M, Pepperl-Klindworth S, Lang D, Vornhagen R, Hinderer W, Weise K, Sonneborn HH, Plachter B (2001) An antigen fragment encompassing the AD2 domains of glycoprotein B from two different strains is sufficient for differentiation of primary vs. recurrent human cytomegalovirus infection by ELISA. J Med Virol 65:719–729PubMedCrossRef
48.
Dauby N, Sartori D, Kummert C, Lecomte S, Haelterman E, Delforge ML, Donner C, Mach M, Marchant A (2016) Limited effector memory B-Cell response to envelope glycoprotein B during primary human cytomegalovirus infection. J Infect Dis 213:1642–1650PubMedCrossRef
49.
Gardner TJ, Tortorella D (2016) Virion glycoprotein-mediated immune evasion by human cytomegalovirus: a sticky virus makes a slick getaway. Microbiol Mol Biol Rev 80:663–677PubMedCrossRef
50.
Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O’Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377:1256–1263PubMedPubMedCentralCrossRef
51.
Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G (2009) Vaccine prevention of maternal cytomegalovirus infection. New Engl J Med 360:1191–1199PubMedPubMedCentralCrossRef
52.
Bernstein DI, Munoz FM, Callahan ST, Rupp R, Wootton SH, Edwards KM, Turley CB, Stanberry LR, Patel SM, Mcneal MM, Pichon S, Amegashie C, Bellamy AR (2016) Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial. Vaccine 34:313–319PubMedCrossRef
53.
Pötzsch S, Spindler N, Wiegers AK, Fisch T, Rucker P, Sticht H, Grieb N, Baroti T, Weisel F, Stamminger T, Martin-Parras L, Mach M, Winkler TH (2011) B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 7:e1002172PubMedPubMedCentralCrossRef
54.
Spindler N, Diestel U, Stump JD, Wiegers AK, Winkler TH, Sticht H, Mach M, Muller YA (2014) Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibody. PLoS Pathog 10:e1004377PubMedPubMedCentralCrossRef
55.
Cui X, Meza BP, Adler SP, McVoy MA (2008) Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26:5760–5766PubMedPubMedCentralCrossRef
56.
57.
Wang D, Shenk T (2005) Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 102:18153–18158PubMedPubMedCentralCrossRef
58.
Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, Wagner M, Gallina A, Milanesi G, Koszinowski U, Baldanti F, Gerna G (2004) Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78:10023–10033PubMedPubMedCentralCrossRef
59.
Adler B, Sinzger C (2013) Cytomegalovirus Interstrain Variance in Cell Type Tropism. In: Reddehase MJ (ed) Cytomegaloviruses From molecular pathogenesis to intervention. Caister Academic Press, Norfolk, pp 297–329
60.
Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S (1998) Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 17:200–206PubMedCrossRef
61.
Wang JB, Adler SP, Hempfling S, Burke RL, Duliege AM, Starr SE, Plotkin SA (1996) Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J Infect Dis 174:387–392PubMedCrossRef
62.
Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B (2012) Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 86:7444–7447PubMedPubMedCentralCrossRef
63.
Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, Lanzavecchia A (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84:1005–1013PubMedCrossRef
64.
Lilleri D, Kabanova A, Revello MG, Percivalle E, Sarasini A, Genini E, Sallusto F, Lanzavecchia A, Corti D, Gerna G (2013) Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One 8:e59863PubMedPubMedCentralCrossRef
65.
Chiuppesi F, Wussow F, Johnson E, Bian C, Zhuo M, Rajakumar A, Barry PA, Britt WJ, Chakraborty R, Diamond DJ (2015) Vaccine-derived neutralizing antibodies to the human cytomegalovirus gH/gL pentamer potently block primary cytotrophoblast infection. J Virol 89:11884–11898PubMedPubMedCentralCrossRef
66.
Fu TM, Wang D, Freed DC, Tang A, Li F, He X, Cole S, Dubey S, Finnefrockter AC, Ter MJ, Shiver JW, Casimiro DR (2012) Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine 30:7469–7474PubMedCrossRef
67.
Wen Y, Monroe J, Linton C, Archer J, Beard CW, Barnett SW, Palladino G, Mason PW, Carfi A, Lilja AE (2014) Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine 32:3796–3804PubMedCrossRef
68.
Wussow F, Chiuppesi F, Martinez J, Campo J, Johnson E, Flechsig C, Newell M, Tran E, Ortiz J, La RC, Herrmann A, Longmate J, Chakraborty R, Barry PA, Diamond DJ (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524PubMedPubMedCentralCrossRef
69.
Kabanova A, Perez L, Lilleri D, Marcandalli J, Agatic G, Becattini S, Preite S, Fuschillo D, Percivalle E, Sallusto F, Gerna G, Corti D, Lanzavecchia A (2014) Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci USA 111:17965–17970PubMedPubMedCentralCrossRef
70.
Hofmann I, Wen Y, Ciferri C, Schulze A, Fuhner V, Leong M, Gerber A, Gerrein R, Nandi A, Lilja AE, Carfi A, Laux H (2015) Expression of the human cytomegalovirus pentamer complex for vaccine use in a CHO system. Biotechnol Bioeng 112:2505–2515PubMedCrossRef
71.
McVoy MA, Lee R, Saccoccio FM, Hartikka J, Smith LR, Mahajan R, Wang JB, Cui X, Adler SP (2015) A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells. Vaccine 33:7328–7336PubMedCrossRef
72.
Britt WJ, Mach M (1996) Human Cytomegalovirus Glycoproteins. Intervirology 39:401–412PubMed
73.
Mach M, Kropff B, Dal Monte P, Britt W (2000) Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). J Virol 74:11881–11892PubMedPubMedCentralCrossRef
74.
Podlech J, Reddehase MJ, Adler B, Lemmermann NA (2015) Principles for studying in vivo attenuation of virus mutants: defining the role of the cytomegalovirus gH/gL/gO complex as a paradigm. Med Microbiol Immunol 204:295–305PubMedCrossRef
75.
Lemmermann NA, Krmpotic A, Podlech J, Brizic I, Prager A, Adler H, Karbach A, Wu Y, Jonjic S, Reddehase MJ, Adler B (2015) Non-redundant and redundant roles of cytomegalovirus gH/gL complexes in host organ entry and intra-tissue spread. PLoS Pathog 11:e1004640PubMedPubMedCentralCrossRef
76.
Corrales-Aguilar, E, Trilling, M, Reinhard, H, Falcone, V, Zimmermann, A, Adams, O, Santibanez, S, Hengel, H (2016) Highly individual patterns of virus-immune IgG effector responses in humans. Med Microbiol Immunol. doi:10.​1007/​s00430-016-0457-y
77.
Eberhardt MK, Deshpande A, Chang WL, Barthold SW, Walter MR, Barry PA (2013) Vaccination against a virus-encoded cytokine significantly restricts viral challenge. J Virol 87:11323–11331PubMedPubMedCentralCrossRef
78.
79.
Reddehase MJ, Mutter W, Münch K, Bühring HJ, Koszinowski UH (1987) CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 61:3102–3108PubMedPubMedCentral
80.
Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238–241PubMedCrossRef
81.
Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New Engl J Med 333:1038–1044PubMedCrossRef
82.
Simon CO, Holtappels R, Tervo HM, Böhm V, Däubner T, Oehrlein-Karpi SA, Kühnapfel B, Renzaho A, Strand D, Podlech J, Reddehase MJ, Grzimek NKA (2006) CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 80:10436–10456PubMedPubMedCentralCrossRef
83.
Ebert S, Podlech J, Gillert-Marien D, Gergely KM, Buttner JK, Fink A, Freitag K, Thomas D, Reddehase MJ, Holtappels R (2012) Parameters determining the efficacy of adoptive CD8 T-cell therapy of cytomegalovirus infection. Med Microbiol Immunol 201:527–539PubMedCrossRef
84.
Ebert S, Lemmermann NA, Thomas D, Renzaho A, Reddehase MJ, Holtappels R (2012) Immune control in the absence of immunodominant epitopes: implications for immunotherapy of cytomegalovirus infection with antiviral CD8 T cells. Med Microbiol Immunol 201:541–550PubMedCrossRef
85.
Reddehase MJ (2016) Mutual interference between cytomegalovirus and reconstitution of protective immunity after hematopoietic cell transplantation. Front Immunol. doi:10.​3389/​fimmu.​2016.​00294
86.
Reusser P, Riddell SR, Meyers JD, Greenberg PD (1991) Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373–1380PubMed
87.
Sissons JG, Wills MR (2015) How understanding immunology contributes to managing CMV disease in immunosuppressed patients: now and in future. Med Microbiol Immunol 204:307–316PubMedCrossRef
88.
Herr W, Plachter B (2009) Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation. Expert Rev Vaccines 8:999–1021PubMedCrossRef
89.
Watkins RR, Lemonovich TL, Razonable RR (2012) Immune response to CMV in solid organ transplant recipients: current concepts and future directions. Expert Rev Clin Immunol 8:383–393PubMedCrossRef
90.
Fernando S, Pearce JM, Booth JC (1993) Lymphocyte responses and virus excretion as risk factors for intrauterine infection with cytomegalovirus. J Med Virol 41:108–113PubMedCrossRef
91.
Stern H, Hannington G, Booth J, Moncrieff D (1986) An early marker of fetal infection after primary cytomegalovirus infection in pregnancy. Br Med J Clin Res 292:718–720CrossRef
92.
Revello MG, Lilleri D, Zavattoni M, Furione M, Genini E, Comolli G, Gerna G (2006) Lymphoproliferative response in primary human cytomegalovirus (HCMV) infection is delayed in HCMV transmitter mothers. J Infect Dis 193:269–276PubMedCrossRef
93.
Lilleri D, Fornara C, Furione M, Zavattoni M, Revello MG, Gerna G (2007) Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus. J Infect Dis 195:1062–1070PubMedCrossRef
94.
Fornara C, Lilleri D, Revello MG, Furione M, Zavattoni M, Lenta E, Gerna G (2011) Kinetics of effector functions and phenotype of virus-specific and gammadelta T lymphocytes in primary human cytomegalovirus infection during pregnancy. J Clin Immunol 31:1054–1064PubMedCrossRef
95.
Fornara C, Furione M, Arossa A, Gerna G, Lilleri D (2016) Comparative magnitude and kinetics of human cytomegalovirus-specific CD4(+) and CD8(+) T-cell responses in pregnant women with primary versus remote infection and in transmitting versus non-transmitting mothers: its utility for dating primary infection in pregnancy. J Med Virol 88:1238–1246PubMedCrossRef
96.
Antoine P, Olislagers V, Huygens A, Lecomte S, Liesnard C, Donner C, Marchant A (2012) Functional exhaustion of CD4+ T lymphocytes during primary cytomegalovirus infection. J Immunol 189:2665–2672PubMedCrossRef
97.
Tabata T, Petitt M, Zydek M, Fang-Hoover J, Larocque N, Tsuge M, Gormley M, Kauvar LM, Pereira L (2015) Human cytomegalovirus infection interferes with the maintenance and differentiation of trophoblast progenitor cells of the human placenta. J Virol 89:5134–5147PubMedPubMedCentralCrossRef
98.
Bialas KM, Tanaka T, Tran D, Varner V, Cisneros DLR, Chiuppesi F, Wussow F, Kattenhorn L, Macri S, Kunz EL, Estroff JA, Kirchherr J, Yue Y, Fan Q, Lauck M, O’Connor DH, Hall AH, Xavier A, Diamond DJ, Barry PA, Kaur A, Permar SR (2015) Maternal CD4+ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission. Proc Natl Acad Sci USA 112:13645–13650PubMedPubMedCentralCrossRef
99.
100.
Früh K, Malouli D, Oxford KL, Barry PA (2013) Non-human-primate models of cytomegalovirus infection, prevention, and therapy. In: Reddehase MJ (ed) Cytomegaloviruses From molecular pathogenesis to intervention. Caister Academic Press, Norfolk, pp 463–496
101.
McVoy, MA, Wang, JB, Dittmer, DP, Bierle, C, Swanson, EC, Fernandez-Alarcon, C, Hernandez-Alvarado, N, Zabeli, JC, Schleiss, MR (2016) Repair of a mutation disrupting the guinea pig cytomegalovirus pentameric complex acquired during fibroblast passage restores pathogenesis in immune suppressed guinea pigs and in the context of congenital infection. J Virol. doi:10.​1128/​JVI.​00320-16
102.
Doerr HW, Berger A (2014) Vaccination against infectious diseases: what is promising? Med Microbiol Immunol 203:365–371PubMedCrossRef
103.
Griffiths P, Plotkin S, Mocarski E, Pass R, Schleiss M, Krause P, Bialek S (2013) Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 31(Suppl 2):B197–B203PubMedCrossRef
104.
105.
Schleiss MR, Plotkin SA (2013) Cytomegalovirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines. Elsevier, Saunders, pp 1032–1041CrossRef
106.
Duryea EL, Sanchez PJ, Sheffield JS, Jackson GL, Wendel GD, McElwee BS, Boney LF, Mallory MM, Owen KE, Stehel EK (2010) Maternal human immunodeficiency virus infection and congenital transmission of cytomegalovirus. Pediatr Infect Dis J 29:915–918PubMedCrossRef
107.
Reitter A, Buxmann H, Haberl AE, Schlosser R, Kreibich M, Keppler OT, Berger A (2016) Incidence of CMV co-infection in HIV-positive women and their neonates in a tertiary referral centre: a cohort study. Med Microbiol Immunol 205:63–71PubMedCrossRef
108.
Manicklal S, van Niekerk AM, Kroon SM, Hutto C, Novak Z, Pati SK, Chowdhury N, Hsiao NY, Boppana SB (2014) Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa. Clin Infect Dis 58:1467–1472PubMedCrossRef
109.
Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR (1996) Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 70:78–83PubMedPubMedCentral
110.
Weber B, Klinghardt U, Lux A, Braun W, Rabenau H, Doerr HW (1993) Detection of neutralizing antibodies against human cytomegalovirus: influence of strain variation. J Med Virol 40:28–34PubMedCrossRef
111.
Chou SW, Dennison KM (1991) Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis 163:1229–1234PubMedCrossRef
112.
Darlington J, Super M, Patel K, Grundy JE, Griffiths PD, Emery VC (1991) Use of the polymerase chain reaction to analyse sequence variation within a major neutralizing epitope of glycoprotein B (gp58) in clinical isolates of human cytomegalovirus. J Gen Virol 72:1985–1989PubMedCrossRef
113.
Hebart H, Greif M, Krause H, Kanz L, Jahn G, Muller CA, Einsele H (1997) Interstrain variation of immediate early DNA sequences and glycoprotein B genotypes in cytomegalovirus clinical isolates. Med Microbiol Immunol Berl 186:135–138PubMedCrossRef
114.
Pignatelli S, Dal MP, Rossini G, Landini MP (2004) Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains. Rev Med Virol 14:383–410PubMedCrossRef
115.
Vogel JU, Otte J, Koch F, Gumbel H, Doerr HW, Cinatl J Jr (2013) Role of human cytomegalovirus genotype polymorphisms in AIDS patients with cytomegalovirus retinitis. Med Microbiol Immunol 202:37–47PubMedCrossRef
116.
Renzette N, Bhattacharjee B, Jensen JD, Gibson L, Kowalik TF (2011) Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog 7:e1001344PubMedPubMedCentralCrossRef
117.
Renzette N, Pokalyuk C, Gibson L, Bhattacharjee B, Schleiss MR, Hamprecht K, Yamamoto AY, Mussi-Pinhata MM, Britt WJ, Jensen JD, Kowalik TF (2015) Limits and patterns of cytomegalovirus genomic diversity in humans. Proc Natl Acad Sci USA 112:E4120–E4128PubMedPubMedCentralCrossRef
118.
Sijmons S, Thys K, Mbong NM, Van DE, Dvorak J, Van LM, Li G, Tachezy R, Busson L, Aerssens J, Van RM, Maes P (2015) High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination. J Virol 89(15):7673–7695PubMedCentralCrossRef
119.
Wilkinson GW, Davison AJ, Tomasec P, Fielding CA, Aicheler R, Murrell I, Seirafian S, Wang EC, Weekes M, Lehner PJ, Wilkie GS, Stanton RJ (2015) Human cytomegalovirus: taking the strain. Med Microbiol Immunol 204:273–284PubMedPubMedCentralCrossRef
120.
Siewiera J, El CH, Tabiasco J, Berrebi A, Cartron G, Le BP, Jabrane-Ferrat N (2013) Human cytomegalovirus infection elicits new decidual natural killer cell effector functions. PLoS Pathog 9:e1003257PubMedPubMedCentralCrossRef
121.
Weisblum Y, Panet A, Zakay-Rones Z, Vitenshtein A, Haimov-Kochman R, Goldman-Wohl D, Oiknine-Djian E, Yamin R, Meir K, Amsalem H, Imbar T, Mandelboim O, Yagel S, Wolf DG (2015) Human cytomegalovirus induces a distinct innate immune response in the maternal-fetal interface. Virology 485:289–296PubMedCrossRef
122.
Ebert S, Becker M, Lemmermann NA, Buttner JK, Michel A, Taube C, Podlech J, Bohm V, Freitag K, Thomas D, Holtappels R, Reddehase MJ, Stassen M (2014) Mast cells expedite control of pulmonary murine cytomegalovirus infection by enhancing the recruitment of protective CD8 T cells to the lungs. PLoS Pathog 10:e1004100PubMedPubMedCentralCrossRef
123.
Podlech J, Ebert S, Becker M, Reddehase MJ, Stassen M, Lemmermann NA (2015) Mast cells: innate attractors recruiting protective CD8 T cells to sites of cytomegalovirus infection. Med Microbiol Immunol 204:327–334PubMedCrossRef
124.
Brinkmann MM, Dag F, Hengel H, Messerle M, Kalinke U, Cicin-Sain L (2015) Cytomegalovirus immune evasion of myeloid lineage cells. Med Microbiol Immunol 204:367–382PubMedCrossRef
125.
Noriega V, Redmann V, Gardner T, Tortorella D (2012) Diverse immune evasion strategies by human cytomegalovirus. Immunol Res 54:140–151PubMedCrossRef
126.
Amsler L, Verweij MC, Defilippis VR (2013) The tiers and dimensions of evasion of the type I interferon response by human cytomegalovirus. J Mol Biol 425:4857–4871PubMedCrossRef
127.
Hansen SG, Wu HL, Burwitz BJ, Hughes CM, Hammond KB, Ventura AB, Reed JS, Gilbride RM, Ainslie E, Morrow DW, Ford JC, Selseth AN, Pathak R, Malouli D, Legasse AW, Axthelm MK, Nelson JA, Gillespie GM, Walters LC, Brackenridge S, Sharpe HR, Lopez CA, Früh K, Korber BT, McMichael AJ, Gnanakaran S, Sacha JB, Picker LJ (2016) Broadly targeted CD8(+) T cell responses restricted by major histocompatibility complex E. Science 351:714–720PubMedCrossRef
128.
Hansen SG, Powers CJ, Richards R, Ventura AB, Ford JC, Siess D, Axthelm MK, Nelson JA, Jarvis MA, Picker LJ, Früh K (2010) Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328:102–106PubMedPubMedCentralCrossRef
129.
Pereira L, Tabata T, Petitt M, Hoover JF (2013) Cytomegalovirus Replication in the Developing Human Placenta. In: Reddehase MJ (ed) Cytomegaloviruses From molecular pathogenesis to intervention. Caister Academic Press, Norfolk, pp 74–87
130.
Weisblum Y, Panet A, Haimov-Kochman R, Wolf DG (2014) Models of vertical cytomegalovirus (CMV) transmission and pathogenesis. Semin Immunopathol 36:615–625PubMedCrossRef
Metadaten
Titel
Prospects of a vaccine for the prevention of congenital cytomegalovirus disease
verfasst von
Bodo Plachter
Publikationsdatum
12.08.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Medical Microbiology and Immunology / Ausgabe 6/2016
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-016-0472-z

Weitere Artikel der Ausgabe 6/2016

Medical Microbiology and Immunology 6/2016 Zur Ausgabe

Original Investigation

Evaluation of cytotoxicity, immune compatibility and antibacterial activity of biogenic silver nanoparticles

Rapid Communication

Classification of Proteus penneri lipopolysaccharides into core region serotypes

Original Investigation

HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy

Original Investigation

High prevalence of human papillomaviruses in Ghanaian pregnant women

Original Investigation

Prevalence of human papillomavirus infection among women presenting for cervical cancer screening in Chile, 2014–2015

Original Investigation

Enhancement of the pathogenicity of Staphylococcus aureus strain Newman by a small noncoding RNA SprX1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Parkinson-Krankheit | Nachrichten

Viel Bewegung in der Parkinsonforschung

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise